Objective:To explore the expression of Netrin-1 protein in human renal clear cell carcinoma (RCCC) and the relationships between Netrin-1, pathology and prognosis. Methods:72 cases of RCCC admitted in our hospital from 2008 June to 2009 June and their adjacent tissues were selected for study. They included 30 cases in stage I-II, 42 cases in stageⅢ-IV;9 cases in grade I, 9 cases in grade II, 40 cases in gradeⅢand 14 cases in grade IV. All cases were followed up for more than 5 years. Survival analysis lines were made by Kaplan—Meier method and the difference between groups was tested by the Log-rank test. The expression of Netrin-1 protein was detected by immunohistochemistry staining and its clinical significance was analyzed. Results:Renal clear cell carcinoma:51 cases in high expression of Netrin-1 and 21 cases in low expression, normal tissues: 12 cases in high expression of Netrin-1 and 60 cases in low expression, the difference between the two groups is significant (χ2=42.921, P<0.01). The difference of the expression of Netrin-1in Fuhrman grade and AJCC clinical stage is significant (χ2=8.000,χ2=6.203;P<0.05). The 5-year survival rate in low protein expression group and in high protein expression group was 79%(17/21) and 62%(32/51). The survival curve had different trend, with no significant difference between groups (χ2=1.360, P=0.245). Conclusions: Netrin-1 protein plays an important role in the development of RCCC. It might be a new specific tumor marker of RCCC, and might become a new target in treatment of RCCC.

Objective To study the expression of p53 and vascular endothelial growth factor(VEGF) in bladder transitional cell carcinoma(BTCC) tissue and its relationship with the clinicopathologic parameters,and to understand the role of p53 and VEGF in the progression of tumors.Methods The expression of p53 and VEGF in 86 cases of BTCC were determined by immunohistochemical LDP methods.Results The positive expression rates of p53 and VEGF in 86 cases of BTCC were 46.51% and 66.28%,respectively.The positive correlation was noted between p53 expression and VEGF expression(P

OBJECTIVETo evaluate the efficacy of Prostat in the treatment of NIH category IIIA prostatitis.

METHODSAn open clinical trial was conducted among 106 NIH category IIIA prostatitis patients. For each patient 1 tablet of Prostat (70 mg P5 + 4 mg EA10) was orally administered twice a day.

RESULTSSubjective symptoms of the patients were significantly improved, particularly those of frequent micturition, urgent urination and peripheral region pains. Objective parameters also showed significant improvement. No adverse reaction associated with the medication was observed.

CONCLUSIONProstat was shown to be an appropriate medicine in the treatment of NIH category IIIA prostatitis, with good curative effect and high safety.

Adult ; Humans ; Male ; Middle Aged ; Phytotherapy ; Pollen ; Prostatitis ; drug therapy ; Treatment Outcome